Publication search

Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumo...

Published in Journal of Thrombosis and Thrombolysis

Critically ill patients with COVID-19 pneumonia suffered both high thrombotic and bleeding risk. The effect of SARS-CoV-2 on coagulation and fibrinolysis is not well known. We conducted a retrospective study of critically ill patients admitted to an intensive care unit (ICU) a cause of severe COVID-19 pneumonia and we evaluated coagulation function...

Fibrinolysis in COVID-19 patients with hemodynamic unstable acute pulmonary embolism: yes or no?

Published in Journal of Thrombosis and Thrombolysis

Sudden death due to acute pulmonary embolism in a young woman with COVID-19

Published in Journal of Thrombosis and Thrombolysis

Coronavirus disease 2019 (COVID-19) is an infectious disease that primarily affects the respiratory system, but it may cause cardiovascular complications such as thromboembolism. Rarely, pulmonary embolism may be encountered in patients with severe COVID-19 infection, especially in intensive care units. An asymptomatic young case of COVID-19 presen...

Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic...

Published in Journal of Thrombosis and Thrombolysis

Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical ...

Published in Journal of Thrombosis and Thrombolysis

Covid-19 treatment update: follow the scientific evidence

Published in Journal of Thrombosis and Thrombolysis

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel

Published in Journal of Thrombosis and Thrombolysis

Platelets aggregation leading to thrombosis plays a pivotal role in the pathophysiology of acute coronary syndrome (ACS) and of stent thrombosis. Antiplatelet therapy with aspirin plus an ADP-receptor inhibitor (ticagrerol, prasugrel or clopidogrel) is recommended to reduce the risk of other platelet-mediated events. Clopidogrel is recommended in p...

Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavi...

Published in Journal of Thrombosis and Thrombolysis

The outbreak of 2019 novel coronavirus disease (COVID-19) began since early December 2019, and has been declared as a public health emergency by the World Health Organization. Due to the hypercoagulable state, blood stasis and endothelial injury, severe patients with COVID-19 are at high risk for thrombosis. We report a case of very severe COVID-19...

Toward understanding the 2019 Coronavirus and its impact on the heart

Published in Journal of Thrombosis and Thrombolysis

Effect of SAMe-TT 2R 2 score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treat...

Published in Journal of Thrombosis and Thrombolysis

There is no strong evidence on pharmacogenetics role on the quality of INR control after the initiation phase and on the maintenance of stable INR on the long term as measured by the time in therapeutic range (TTR). The benefit of a score such as SAMe-TT2R2 is that it can preemptively guide clinicians on whether to start the patient on warfarin or ...